Author

R. Iacovelli

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Safety profile of BCG with or without immunotherapy in non–muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis

Background Intravesical bacillus Calmette-Guérin (BCG) is the standard of care for BCG-naïve high-risk non–muscle-invasive bladder cancer (NMIBC). Recent phase III trials showed reduced disease recurrence with the addition of immune checkpoint inhibitors (ICIs) to BCG induction plus maintenance but with increased toxic...

C. Ciccarese, D. Occhipinti, P. Troisi et al. · ESMO Open · 1 citation

Open access Sep 2026

34 Belzutifan Plus Lenvatinib Versus Cabozantinib in Post–PD-(L)1 Renal Cell Carcinoma: Health-Related Quality-of-Life Outcomes in the Phase 3 LITESPARK-011 Study

Abstract Background Belzutifan plus lenvatinib significantly improved progression-free survival and objective response rate versus cabozantinib, and had manageable safety, in participants with advanced renal cell carcinoma (RCC) that progressed on or after anti-programmed cell death protein 1 and anti-programmed cell d...

M. Schmidinger, Daniel Y. C. Heng, Ray McDermott et al. · The Oncologist · 0 citations

Open access Sep 2026

1 Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Renal Cell Carcinoma: Patient-Reported Outcomes in LITESPARK-022

Abstract Background The randomized, double-blind, phase 3 LITESPARK-022 study (NCT05239728) showed significant disease-free survival benefit with the addition of belzutifan to adjuvant pembrolizumab in participants with clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence following surgery. We presen...

T. Powles, T. Choueiri, J. Karam et al. · The Oncologist · 0 citations